"If we can just get this to a vote, it will be pretty hard for people to vote against it. A vote against this is a vote against consumers." -- A pharmaceutical/patent related bill has stalled in the Senate, thanks to heavy industry lobbying. The bill would ban payments from drug manufacturers (i.e. patent holders) to generic drugmakers in exchange for the delay of a generic version of a drug. How does this fit into your understanding of the patent public domain process? And keep it in mind with next week's reading on IP ethics...